Medivation Inc./Astellas Pharma Inc. have been handed an opportunity to sharpen up the regulatory strategy for their prostate cancer drug enzalutamide (MDV3100) after data from the Phase III COUGAR-302 trial, testing Johnson & Johnson’s Zytiga (abiraterone) in pre-chemotherapy patients, were revealed at the American Society of Clinical Oncology meeting in Chicago.
The Zytiga trial was stopped in March after an interim analysis showed significant improvement in radiological progression-free survival for the...